<?xml version="1.0" encoding="UTF-8"?>
<p>Nevertheless, the 
 <italic>T. arjuna</italic> (Roxb. ex DC.) Wight &amp; Arn. treatment, even when it was well-tolerated, did not change the left ventricular ejection fraction or secondary outcome measures. The third report evaluated the cardioprotective effect of 
 <italic>T. arjuna</italic> (Roxb. ex DC.) Wight &amp; Arn. on classical and immuno-inflammatory markers in coronary artery disease by administering 500 mg twice a day to eight patients. 
 <italic>Terminalia</italic> sp. treatment significantly down-regulated the triglycerides, VLDL-C, and immune-inflammatory markers in stable coronary artery disease after 3 months, and the effect was maintained after 6 months with decreased total cholesterol levels.
</p>
